Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 7 of 7 for “"TKI resistance"”.
-
A Role For Lipid Rafts In Egfr Tki Resistance In Breast Cancer
… cell lines to determine a potential mechanism of resistance to EGFR-targeted small molecule tyrosine kinase inhibitors (TKIs). Specifically, we have shown that EGFR localizes to discrete membrane microdomains (lipid rafts) in cell lines that are resistant to EGFR TKI-induced growth inhibition. …
-
Uncovering Molecular Targets to Overcome Immunosuppression In Non-Small Cell Lung Cancer With Acquired Tki Resistance
… receptor (EGFR) tyrosine kinase inhibitors (TKIs) or monoclonal antibodies targeting vascular endothelial growth factor (VEGF/R), can effectively inhibit upregulated signaling pathways driving tumorigenesis in NSCLC and many other cancers. Unfortunately, however, resistance to such targeted …
-
INTERPLAY BETWEEN MDM2 AND TFAM REGULATES OXIDATIVE PHOSPHORYLATION IN DRUG-RESISTANT ONCOGENE-ADDICTED CANCERS
Tyrosine kinase inhibitors (TKI) remain the first-line treatment for most oncogene-addicted cancers. However, prolonged exposure to TKI could lead to development of resistance. There is mounting evidence of OXPHOS dependency as a mechanism of TKI resistance, but the cause of this metabolic switch …
-
The analysis of Bcr-Abl—Nox signalling in chronic myeloid leukaemia
… of Bcr-Abl-specific tyrosine kinase inhibitors (TKIs) there has been a substantial improvement in the clinical treatment of CML. Unfortunately, residual disease and the development of TKI resistance has become an ever growing concern, resulting in the need for a greater understanding of the …
-
Novel treatment strategy for ALK-positive Anaplastic Large Cell Lymphoma
… Single-agent use of tyrosine kinase inhibitors (TKI) to inhibit ALK is a conventional second-line treatment and has been trialled for upfront use in combination with the ALCL99 therapeutic backbone. However, an extended duration of treatment is required as cessation of therapy can lead to rapid …
-
TARGETING THE DNA DAMAGE RESPONSE PATHWAY FOR THE TREATMENT OF AGGRESSIVE THYROID CANCERS, IN VITRO STUDIES
… line treatments and tyrosine kinase inhibitors (TKIs). Though, part of them as well as Poorly Differentiated and Anaplastic TC are particularly aggressive and refractory both to first-line and TKI treatments, such as Lenvatinib (LENV). In other aggressive tumours (NSCLC, HCC, CML), TKI resistance …
-
Studying the Transcriptional and Epigenetic Perturbations of Haematopathologies Expressing NPM1-ALK
… therapeutics (ALK-tyrosine kinase inhibitors; TKI) have been used in the treatment of ALK-driven cancers. Unfortunately, clinical and research studies have suggested that resistance to ALK inhibitors can develop through mutation or activation of ALK signalling bypass tracks. As such, a need for …